Zero Dropouts. 100% Success. Here’s How. ProRelix Research's Approach to Reinventing Pinguecula & Pterygium Treatment with a Novel Eye Drop Therapy!

ProRelix Research was approached by a biotech company to manage a critical Phase I/II clinical trial involving an innovative eye drop formulation targeting pinguecula and pterygium, two common yet often underappreciated eye conditions. The sponsor was a biopharma company based in the Middle East, known for its innovative approach to treating ophthalmic diseases. The trial was pivotal for both the sponsor and the patients involved. These eye conditions, although common, often have limited therapeutic options. For many patients suffering from these diseases, there were few treatment alternatives, and surgical interventions were the only other option, which came with significant risks and recovery times. The introduction of this eye drop formulation could revolutionize the treatment landscape for these patients.

The sponsor needed a CRO for early and late phase clinical trials that could successfully navigate complex regulatory environments, deliver within tight timelines, and manage a limited patient pool. The trial required careful planning, innovative patient recruitment strategies, and meticulous oversight, which ProRelix Research was well-equipped to provide.

Who was the sponsor?

The sponsor was a biotech company, headquartered in the Middle East, specializing in ophthalmic treatments. Their goal was to provide more effective and non-invasive treatments for pinguecula and pterygium, two conditions that affect the eyes and can lead to impaired vision and discomfort.

What was the product/intervention under study?

The product being studied was a novel eye drop formulation. This was a new approach to treating pinguecula and pterygium, which are growths on the eye’s conjunctiva. Traditionally, these conditions were treated with surgical removal, a procedure that carries risks and requires significant recovery time. The eye drops represented a non-invasive, potentially safer alternative
for patients.

Why was the trial important?

This trial was significant for several reasons. First, it explored an off-label indication for a known molecule, offering the possibility of a new treatment option for patients with these specific eye conditions. Second, there was a strong potential to improve the quality of life for patients who often had limited therapeutic options. The non-invasive nature of the product could provide easier, safer alternatives for those with these eye conditions, many of whom were often forced to undergo surgery.Additionally, this trial was crucial for regulatory approval and the eventual market launch of the product. The results of the trial would help determine whether the product could be brought to market and provide a valuable tool for ophthalmologists treating pinguecula and pterygium.

Challenges

Tight Timelines

The trial had to be completed within a strict timeframe in order to meet regulatory deadlines. Given the complexities of managing clinical trials for novel treatments, meeting these timelines required agility and efficiency.

Regulatory Complexity

As the treatment was off-label, it introduced regulatory challenges regarding approval for its clinical use. Navigating complexities & ensuring adherence to international regulations was a priority for us.

Limited Patient Pool

Pinguecula and pterygium are conditions that typically affect a smaller patient pool, especially when considering specific inclusion and exclusion criteria. Recruiting enough participants for the trial would require innovative recruitment strategies and strong patient engagement.

What were the initial challenges?

Several key challenges presented themselves during the early phases of the trial. We approached this trial with a strategic mindset focused on innovation, efficiency, and patient-centric design. Our approach was driven by a few key pillars.

Solution: How did we tackle the challenge?

Optimized Protocol Design: ProRelix Research worked closely with the sponsor to develop an optimized trial protocol. The protocol was designed to ensure scientific rigor while also being practical and feasible. We considered the specific needs of patients, the regulatory landscape, and the logistical constraints of managing a multi-site trial.
Rapid Regulatory Strategy: Given the complexity of the regulatory environment, we focused on securing regulatory approvals early in the process. We ensured that all documents, including ethics committee approvals, were submitted swiftly and followed up rigorously.
Efficient Site Selection and Onboarding: To ensure timely patient recruitment, we targeted high-performing sites that had the expertise in ophthalmology and the infrastructure to carry out clinical trials. We began discussions with key sites early and streamlined the onboarding process.

Solution: What made our approach unique or efficient?

Technology-Driven Monitoring: ProRelix Research utilized cutting-edge real-time monitoring tools to track the trial’s progress. Our team was able to assess data continuously, allowing us to identify and address potential challenges before they impacted the timeline.
Remote Monitoring Tools: With the COVID-19 pandemic still a concern in certain areas, we Implemented remote consultations and monitoring systems. This innovation allowed patients to participate without needing to travel extensively, enhancing patient recruitment and retention.
Patient-Centric Recruitment Strategies: We used digital tools like social media campaigns, partnerships with patient advocacy groups, and local advertisements to reach potential participants. These campaigns helped us to enroll the target number of patients within the allocated time frame, despite the smaller patient pool for this condition.

Solution: What services did we provide?

ProRelix Research provided a comprehensive range of services to ensure the success of this trial, including:

Protocol Design: Tailored to ensure patient safety, regulatory compliance, and the best chance of successful outcomes.
Site Selection: Conducted with a focus on high-quality investigators and clinics with relevant experience in ophthalmic trials.
Regulatory Submission: Ensured the rapid submission and approval of regulatory documents, keeping the trial on schedule.
Monitoring: Employed real-time monitoring systems, site visits, and remote audits to ensure compliance with protocol and data integrity.
Patient Recruitment & Retention: Utilized innovative patient engagement techniques to maintain a high retention rate throughout the study.

Execution:

The execution phase of the trial was marked by unprecedented success. ProRelix Research’s meticulous planning and strategic implementation allowed the trial to proceed smoothly despite the inherent challenges.

What was the execution timeline?

The trial was executed over a 12-month period, from initiation to database lock. Given the complex regulatory environment and the need for precise data collection, this timeline was considered aggressive but achievable with the right strategy.
Recruitment was completed ahead of schedule, allowing for a fast start and further accelerating trial progress.
Data Lock occurred within 7 days of the last-patient-last-visit (LPLV), a testament to the efficiency of our operations and the clean data produced. Innovative Tools and Methods Used
eCRF and Telemedicine Integration: To ensure seamless data capture and remote participation, ProRelix Research integrated eCRF (electronic case report forms) into the trial workflow. This provided both the site and patients with easy-to-use tools that ensured high data quality and compliance. Additionally, we utilized telemedicine consultations to facilitate patient visits and reduce the need for frequent site visits.
Advanced Analytics & Dashboards: We employed real-time dashboards to track progress across all sites, allowing for adaptive trial management. Predictive analytics helped us foresee any potential delays or issues, enabling us to act proactively and adjust as necessary.
Patient Recruitment Campaigns: We launched targeted online campaigns, collaborated with patient advocacy groups, and used local clinics to ensure maximum recruitment. This strategy helped us overcome the typical challenges associated with recruiting a limited patient pool for rare conditions.

Collaboration with Sites and Stakeholders:

We worked closely with a top-tier hospital and ophthalmic research center to ensure the study was executed to the highest standards. Regular meetings and open communication channels with the sponsor and sites ensured that everyone was aligned and working towards the same goal.

Outcomes : The results of the trial were nothing short of exceptional.

100% Enrollment Ahead of Schedule: Despite the challenges posed by the limited patient pool, we completed patient recruitment early and exceeded enrollment expectations.
Zero Dropouts: All enrolled patients remained in the study for its duration, a rare and remarkable achievement in clinical trials.
Clean Data: Our emphasis on data integrity resulted in 100% clean data, with no critical findings in regulatory inspections.
Rapid Data Lock: The database lock was completed within 7 days of LPLV, ensuring the sponsor could proceed with regulatory submissions without delay.

How did it benefit the client?

The successful completion of the trial provided the sponsor with valuable clinical data, allowing them to pursue global regulatory approval. This was a significant milestone for the sponsor’s product, as it opened the door for future clinical development and market launch. Moreover, the timely completion of the trial helped the sponsor meet their regulatory deadlines, positioning them for success in an increasingly competitive market.

“ProRelix Research became an extension of our internal team. They delivered results that exceeded our expectations. The quality of their work and their commitment to the trial’s success were unparalleled. We are now looking forward to continuing our partnership with them in future trials.”

- Clinical Program Lead, Biotech Sponsor

Did it lead to further work, approvals, or milestones?

The success of this trial laid the groundwork for future studies and global regulatory submissions. The sponsor, impressed with our ability to deliver high-quality results on time, has already approached ProRelix Research for subsequent trials and additional work in the ophthalmology space.

Takeaway / What This Project Taught Us

This trial taught us several valuable lessons, particularly regarding the importance of proactive planning and patient-centered approaches. Key takeaways include:

The value of early risk mitigation and planning for potential challenges.
How remote tools and telehealth can significantly enhance patient engagement and retention.
The critical role of real-time monitoring in adaptive trial management.

This experience will undoubtedly shape how we approach future trials, especially when dealing with complex regulatory challenges and underserved patient populations. We are more committed than ever to driving innovation and improving patient outcomes in clinical research.

If your trial demands more than routine execution—if it needs precision, agility, and patient delight—partner with ProRelix Research. Because we don’t just conduct trials. We create impact.

View More Case Studies

How we helped a biotech innovator overcome clinical trial obstacles: A journey to success

We understand that every clinical trial is a race against time. Our expertise in patient recruitment, regulatory approvals, and site management has helped biotech and pharmaceutical companies successfully bring life-saving treatments to market faster.

Zero Dropouts. 100% success. Here's How: ProRelix Research’s Approach to Reinventing Pinguecula & Pterygium Treatment with a Novel Eye Drop Therapy!

ProRelix Research was approached by a biotech company to manage a critical Phase I/II clinical trial involving an innovative eye drop formulation targeting

From Pandemic Pressure to Promising Potential: How We Fast-Tracked a COVID-19 Clinical Trial on an Emerging Investigational Antiviral Therapy

A Global Crisis Calls for Immediate Action: The outbreak of COVID-19 in late 2019 turned the world upside down, resulting in significant loss of life, overwhelming healthcare systems, and

the trial that will redefine gi motility disorder treatment prorelix research’s unprecedented findings on safety and efficacy of a traditional polyherbal formulation

The Trial That Will Redefine GI Motility Disorder Treatment: ProRelix's Unprecedented Findings on Safety and Efficacy of a Traditional Polyherbal Formulation

In the realm of gastrointestinal health, motility disorders continue to challenge both patients and physicians alike. Symptoms such as bloating, indigestion, abdominal discomfort, and irregular bowel habits often go undiagnosed or are

2 Pills That Could Save Lives? Inside the COVID Trial That Changed Everything

In the turbulent wake of the COVID-19 pandemic, when hospitals overflowed and oxygen cylinders became as precious as gold, the global medical community was united by one pressing question: How do we reduce mortality in moderate COVID-19 cases before they deteriorate into critical, ICU-level emergencies?

We Ran a 90-Day Clinical Trial on a Longevity Compound—Here’s What Changed in Just 3 Months

In an era where the lines between biotechnology and longevity science blur more each day, one compound has captured the attention of both researchers and the health-conscious public alike. Known for its potential to boost cellular energy levels and combat biological ageing, it has rapidly emerged

Email Us

info@prorelixresearch.com

Our Story

For Regulatory Submission

For Claims Support

Therapeutic Expertize

Zero Dropouts. 100% Success. Here’s How. ProRelix Research's Approach to Reinventing Pinguecula & Pterygium Treatment with a Novel Eye Drop Therapy!